Tirzepatide 45mg

Tirzepatide is a novel synthetic peptide that functions as a dual agonist at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism distinguishes it from single-receptor GLP-1 agonists and has made it a subject of considerable scientific interest in the field of metabolic research. By activating both incretin receptors simultaneously, tirzepatide research models demonstrate enhanced effects on insulin secretion, glucagon suppression, gastric emptying, and appetite regulation compared to GLP-1 mono-agonism alone.

In preclinical and clinical research settings, tirzepatide has been extensively studied for its pronounced effects on body weight reduction, glycaemic control, and lipid metabolism. Research applications include investigation of obesity pathophysiology, type 2 diabetes mechanisms, cardiovascular metabolic risk, and energy homeostasis. Its unique receptor co-agonism profile also makes it valuable for comparative pharmacological studies examining the distinct and synergistic contributions of GIP and GLP-1 signalling pathways.

This 45mg research quantity is supplied as a lyophilised powder with a purity of >98% as verified by HPLC analysis. Store lyophilised product at -20°C; once reconstituted, store at 4°C and use within 14 days.

For research purposes only. Not for human use. This product is intended solely for in vitro and preclinical research applications by qualified professionals.